影像组学能否预测IV期非小细胞肺癌化疗期间骨骼肌变化
本研究基于116例IV期非小细胞肺癌患者的随机对照试验数据,事后分析骨骼肌影像组学特征能否预测化疗期间肌肉丢失。
要点
- IV期NSCLC化疗期间59%患者出现骨骼肌丢失。
- 骨骼肌影像组学预测肌肉丢失的AUC仅0.49。
- 影像组学特征随时间变化可能反映肌肉脂肪浸润。
核心结论
- 骨骼肌影像组学未能预测IV期非小细胞肺癌化疗期间的肌肉丢失。
- 影像组学特征随时间的变化可能反映肌肉脂肪浸润。
研究设计与样本
- 事后分析纳入116例IV期非小细胞肺癌患者,来自一项研究硝酸甘油联合紫杉醇-卡铂-贝伐珠单抗的随机对照试验(NCT01171170)。
- 从化疗前及第二周期后CT图像提取肌肉横截面积和影像组学特征,随机拆分训练集与验证集100次进行内部交叉验证,采用LASSO筛选特征并以AUC评估模型性能。
主要发现
- 有和无肌肉丢失的患者间,影像组学强度和纹理特征随时间变化存在差异。
临床怎么用
- 目前骨骼肌影像组学尚不能用于预测IV期NSCLC化疗期间的肌肉丢失。
局限性
- 本研究为事后分析,样本量有限(116例),需外部验证。
- 影像组学特征与肌肉脂肪浸润的生物学关联尚未明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Muscle depletion negatively impacts treatment efficacy and survival rates in cancer. Prevention and timely treatment of muscle loss require prediction of patients at risk. We aimed to investigate the potential of skeletal muscle radiomic features to predict future muscle loss. METHODS: A total of 116 patients with stage IV non-small cell lung cancer included in a randomised controlled trial (NCT01171170) studying the effect of nitroglycerin added to paclitaxel-carboplatin-bevacizumab were enrolled. In this post hoc analysis, muscle cross-sectional area and radiomic features were extracted from computed tomography images obtained before initiation of chemotherapy and shortly after administration of the second cycle. For internal cross-validation, the cohort was randomly split in a training set and validation set 100 times. We used least absolute shrinkage and selection operator method to select features that were most significantly associated with muscle loss and an area under the curve (AUC) for model performance. RESULTS: Sixty-nine patients (59%) exhibited loss of skeletal muscle. One hundred ninety-three features were used to construct a prediction model for muscle loss. The average AUC was 0.49 (95% confidence interval [CI]: 0.36, 0.62). Differences in intensity and texture radiomic features over time were seen between patients with and without muscle loss. CONCLUSIONS: The present study shows that skeletal muscle radiomics did not predict future muscle loss during chemotherapy in non-small cell lung cancer. Differences in radiomic features over time might reflect myosteatosis. Future imaging analysis combined with muscle tissue analysis in patients and in experimental models is needed to unravel the biological processes linked to the radiomic features.
引用
- de Jong EEC, Sanders KJC, Deist TM, et al. Can radiomics help to predict skeletal muscle response to chemotherapy in stage IV non-small cell lung cancer? Eur J Cancer. 2019. PMID: 31514107. doi:10.1016/j.ejca.2019.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。